documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
1,713,911 rows sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
posted_year >30
- 2018 106,690
- 2016 98,713
- 2019 91,918
- 2015 80,499
- 2024 78,228
- 2023 73,203
- 2017 72,886
- 2021 71,789
- 2022 71,318
- 2020 69,829
- 2006 68,985
- 2014 65,338
- 2007 63,922
- 2011 61,511
- 2025 61,376
- 2013 61,338
- 2012 60,059
- 2010 56,532
- 2008 55,828
- 2009 54,066
- 2004 47,970
- 2005 47,206
- 2003 34,977
- 2002 28,411
- 2026 21,289
- 2001 20,449
- 2000 19,990
- 1999 17,091
- 1998 14,407
- 1995 13,108
- …
agency_id >30
- EPA 486,212
- FDA 225,683
- DOT 194,125
- FAA 192,831
- BIS 56,803
- FMCSA 49,212
- SEC 41,970
- PHMSA 38,191
- FERC 37,545
- USCG 32,732
- OSHA 31,908
- NHTSA 28,862
- FRA 28,087
- FWS 15,794
- NRC 15,664
- NOAA 15,286
- USTR 13,623
- ITA 13,273
- NIH 13,161
- MARAD 11,632
- FCC 10,117
- ED 9,633
- FEMA 9,340
- VA 7,743
- CMS 7,157
- HUD 7,140
- APHIS 6,194
- DOE 5,349
- USPS 5,323
- CPSC 4,957
- …
document_type 5
- Other 656,504
- Supporting & Related Material 610,632
- Notice 316,165
- Rule 88,070
- Proposed Rule 42,540
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DOT-OST-2002-12555-0308 | DOT | None DOT-OST-2002-12555 | American Airlines, Inc. | Other | Correspondence | 2026-12-13T05:00:00Z | 2026 | 12 | 2025-10-28T04:00:00Z | 2026-02-14T13:14:34Z | 1 | 0 | 09000064b9056fb2 | ||
| FWS-HQ-NWRS-2026-1618-0002 | FWS | Wilderness Administration and Resource Stewardship; Managing Climbing Activities in Wilderness FWS-HQ-NWRS-2026-1618 | USFWS_Public_Review_Sec122_EXPLORE_Act_Rock_Climbing_Guidance_20260615 | Supporting & Related Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T17:50:20Z | 0 | 0 | 09000064b932c780 | ||||
| FWS-HQ-NWRS-2026-2575-0001 | FWS | Wilderness Administration and Resource Stewardship; Request for Information FWS-HQ-NWRS-2026-2575 | Wilderness Administration and Resource Stewardship; Request for Information | Notice | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-08-15T03:59:59Z | 2026-06-15T15:43:00Z | 2026-11956 | 1 | 0 | 09000064b932a25c | |
| FWS-R7-ES-2025-0506-0006 | FWS | Marine Mammals; Proposed Incidental Harassment Authorization for the Southern Beaufort Sea Stock of Polar Bears in the Prudhoe Bay area of the North Slope Borough, Alaska; Draft Environmental Assessment FWS-R7-ES-2025-0506 | 25-IHA-03_Foggy Island_Draft EA | Supporting & Related Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:45:13Z | 0 | 0 | 09000064b9324bc6 | ||||
| FWS-R7-ES-2025-0506-0004 | FWS | Marine Mammals; Proposed Incidental Harassment Authorization for the Southern Beaufort Sea Stock of Polar Bears in the Prudhoe Bay area of the North Slope Borough, Alaska; Draft Environmental Assessment FWS-R7-ES-2025-0506 | 25-IHA-03_Foggy Island_Literature Cited | Supporting & Related Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:45:12Z | 0 | 0 | 09000064b9324bc4 | ||||
| FWS-HQ-NWRS-2026-1618-0001 | FWS | Wilderness Administration and Resource Stewardship; Managing Climbing Activities in Wilderness FWS-HQ-NWRS-2026-1618 | Wilderness Administration and Resource Stewardship; Managing Climbing Activities in Wilderness | Notice | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-08-15T03:59:59Z | 2026-06-15T15:31:46Z | 2026-11970 | 1 | 0 | 09000064b932a25b | |
| FWS-R7-ES-2025-0506-0007 | FWS | Marine Mammals; Proposed Incidental Harassment Authorization for the Southern Beaufort Sea Stock of Polar Bears in the Prudhoe Bay area of the North Slope Borough, Alaska; Draft Environmental Assessment FWS-R7-ES-2025-0506 | 25-IHA-03_Foggy Island_IHA Application | Supporting & Related Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:45:13Z | 0 | 0 | 09000064b9324bc7 | ||||
| FWS-R7-ES-2025-0506-0005 | FWS | Marine Mammals; Proposed Incidental Harassment Authorization for the Southern Beaufort Sea Stock of Polar Bears in the Prudhoe Bay area of the North Slope Borough, Alaska; Draft Environmental Assessment FWS-R7-ES-2025-0506 | 25-IHA-03_Foggy Island_Model and R Code Files | Supporting & Related Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:45:13Z | 0 | 0 | 09000064b9324bc5 | ||||
| FWS-R7-ES-2025-0506-0003 | FWS | Marine Mammals; Proposed Incidental Harassment Authorization for the Southern Beaufort Sea Stock of Polar Bears in the Prudhoe Bay area of the North Slope Borough, Alaska; Draft Environmental Assessment FWS-R7-ES-2025-0506 | 25-IHA-03_Foggy Island_Supplemental Information | Supporting & Related Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:45:12Z | 0 | 0 | 09000064b9324bc3 | ||||
| FDA-2026-H-6513-0001 | FDA | DAB Civil Money Penalty; Nahkai - Ming Enterprise, LLC d/b/a Smoke House FDA-2026-H-6513 | Complaint | Other | Complaint | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T23:19:07Z | 0 | 0 | 09000064b933102e | ||
| FDA-2026-H-6515-0001 | FDA | DAB Civil Money Penalty; Deyanira Izaguirre Martinez d/b/a Martinez Mini Mart & Taqueria FDA-2026-H-6515 | Complaint | Other | Complaint | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T23:17:28Z | 0 | 0 | 09000064b9330741 | ||
| FDA-2024-V-1078-0004 | FDA | Laser Light Show FDA-2024-V-1078 | Variance Renewal from Dog From the Moon LLC | Other | Request | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T22:31:13Z | 0 | 0 | 09000064b93240f7 | ||
| FDA-2024-V-4985-0005 | FDA | Laser Light Show FDA-2024-V-4985 | Variance Approval Letter from FDA CDRH to Projectile Objects LLC | Other | Approval for Variance (VRA) | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T21:53:48Z | 0 | 0 | 09000064b9329753 | ||
| FDA-2026-V-4560-0003 | FDA | Laser Light Show FDA-2026-V-4560 | Variance Approval Letter from FDA CDRH to DJZ Productions | Other | Approval for Variance (VRA) | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T22:28:26Z | 0 | 0 | 09000064b932e7fb | ||
| FDA-2026-V-4031-0003 | FDA | Laser Light Show FDA-2026-V-4031 | Variance Approval Letter to David Wilson | Other | Approval for Variance (VRA) | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T22:28:17Z | 0 | 0 | 09000064b932fd41 | ||
| FDA-2026-P-6737-0039 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 37 - Gadolinium Contrast Agent Deposition in Children | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:30Z | 0 | 0 | 09000064b932a339 | |||
| FDA-2026-P-6737-0035 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 33 - Acute respiratory distress syndrome after the use of gadolinium contrast agent. | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:16Z | 0 | 0 | 09000064b932a32b | |||
| FDA-2026-P-6737-0029 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 27 - Gadolinium during human pregnancy following administration of gadolinium chelate before pregnancy | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:52Z | 0 | 0 | 09000064b932a325 | |||
| FDA-2026-P-6737-0038 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 36 - Effects of gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:26Z | 0 | 0 | 09000064b932a338 | |||
| FDA-2026-P-6737-0034 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 32 - Caught in the act Allergic-like reaction to | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:10Z | 0 | 0 | 09000064b932a32a | |||
| FDA-2026-P-6737-0020 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 18 - Deposition of Gadolinium in the Central and Peripheral Nervous Systems and Its Effects on Sensory | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:22Z | 0 | 0 | 09000064b932a310 | |||
| FDA-2026-P-6737-0027 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 25 - INDUCTION OF EXPRESSION OF PROFIBROTIC CYTOKINES | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:46Z | 0 | 0 | 09000064b932a323 | |||
| FDA-2026-P-6737-0032 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 30 - Comparison of Human Tissue Gadolinium Retention and Elimination between Gadoteridol and Gadobenate | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:03Z | 0 | 0 | 09000064b932a328 | |||
| FDA-2026-P-6737-0025 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 23 - Assessment of gadolinium and iodine concentrations in kidney stones | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:40Z | 0 | 0 | 09000064b932a315 | |||
| FDA-2026-H-6514-0001 | FDA | DAB Civil Money Penalty; Jorgui Corporation d/b/a Broadway Wine & Liquors FDA-2026-H-6514 | Complaint | Other | Complaint | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T23:07:07Z | 0 | 0 | 09000064b9330744 | ||
| FDA-2026-V-4031-0002 | FDA | Laser Light Show FDA-2026-V-4031 | Acknowledgment Letter from FDA DMB to David Wilson | Other | Acknowledgement Letter/Receipt | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T22:28:12Z | 0 | 0 | 09000064b927c6a7 | ||
| FDA-2026-P-6737-0002 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Acknowledgement Letter from FDA DMB to Regina Sutton | Other | Acknowledgement Letter/Receipt | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T20:27:18Z | 0 | 0 | 09000064b9329d18 | ||
| FDA-2026-P-6737-0001 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Citizen Petition from Regina Sutton | Other | Citizen Petition | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T20:27:13Z | 1 | 0 | 09000064b9329d15 | ||
| FDA-2026-P-6737-0042 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 40 - The involvement of proinflammatory cytokines in nephrogenic systemic fibrosis | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:40Z | 0 | 0 | 09000064b932a33c | |||
| FDA-2026-P-6737-0036 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 34 - Immediate Adverse Reactions to Gandolinium-Based MR Contrast Media | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:20Z | 0 | 0 | 09000064b932a336 | |||
| FDA-2026-H-6519-0001 | FDA | DAB Civil Money Penalty; Victor H Ozuna d/b/a Vico's Drive Thru FDA-2026-H-6519 | Complaint | Other | Complaint | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T19:57:58Z | 0 | 0 | 09000064b932eb25 | ||
| FDA-2026-P-6737-0016 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 14 - Contrast-free identification of glioma blood-brain barrier status via generative diffusion AI and non-contrast MRI | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:09Z | 0 | 0 | 09000064b932a30c | |||
| FDA-2026-P-6737-0013 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 11 - On the interaction of muscle actin with gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:58Z | 0 | 0 | 09000064b932a307 | |||
| FDA-2026-P-6737-0022 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 20 - Human Hair as a Possible Surrogate Marker of Retained Tissue | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:30Z | 0 | 0 | 09000064b932a312 | |||
| FDA-2026-P-6737-0014 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 12 - Skin-Related Adverse Reactions in Gadolinium-Based Contrast Agents-Induced Hypersensitivity | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:02Z | 0 | 0 | 09000064b932a308 | |||
| FDA-2026-P-6789-0001 | FDA | Requests that the FDA review whether the two primary generic bicalutamide tablet suppliers can assure the safety, efficacy, and quality of bicalutamide tablets for the intended prostate cancer patient population. FDA-2026-P-6789 | Citizen Petition from Buchanan Ingersoll & Rooney PC | Other | Citizen Petition | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-16T00:57:45Z | 1 | 0 | 09000064b932ff38 | ||
| FDA-2022-V-0385-0005 | FDA | Laser Light Show FDA-2022-V-0385 | Variance Renewal Approval Letter to Brent Parrish | Other | Approval for Variance (VRA) | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T22:55:51Z | 0 | 0 | 09000064b932fd52 | ||
| FDA-2026-H-6636-0001 | FDA | DAB Civil Money Penalty; Express II Corp. d/b/a Express Mart FDA-2026-H-6636 | Complaint | Other | Complaint | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T23:04:37Z | 0 | 0 | 09000064b932fe34 | ||
| FDA-2026-V-4560-0001 | FDA | Laser Light Show FDA-2026-V-4560 | Variance Application from DJZ Productions | Other | Application for Variance (VAR) | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T22:27:28Z | 0 | 0 | 09000064b92a571b | ||
| FDA-2016-V-1231-0006 | FDA | Variance Request for Class IIIB laser Systems in the MAWL family of products: Models: MAWL-DA, MAWL-DA-B FDA-2016-V-1231 | Variance Renewal Request from B.E. Meyers & Company, Inc. | Other | Request | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T23:16:59Z | 0 | 0 | 09000064b932fd74 | ||
| FDA-2026-P-6737-0026 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 24 - Effects of Gadolinium-Based MRI Contrast | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:43Z | 0 | 0 | 09000064b932a322 | |||
| FDA-2026-P-6737-0004 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 2 - Gadolinium-based MRI contrast agent effects on calcium signaling | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:30Z | 0 | 0 | 09000064b932a274 | |||
| FDA-2026-P-6737-0033 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 31 - Gadolinium-based contrast agent-induced neurotoxicity seeing is believing | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:07Z | 0 | 0 | 09000064b932a329 | |||
| FDA-2026-P-6737-0031 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 29 - Acute lung injury following gadolinium contrast | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:00Z | 0 | 0 | 09000064b932a327 | |||
| FDA-2026-P-6737-0028 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 26 - Neurotoxicity from intrathecal gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:49Z | 0 | 0 | 09000064b932a324 | |||
| FDA-2026-P-6737-0017 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 15 - Gadolinium based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:11Z | 0 | 0 | 09000064b932a30d | |||
| FDA-2026-P-6737-0011 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 9 - Gadolinium Mitochondrial Toxicity | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:52Z | 0 | 0 | 09000064b932a305 | |||
| FDA-2026-P-6737-0019 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 17 - Effects of Salicylate and Lanthanides on Outer Hair Cell Motility | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:19Z | 0 | 0 | 09000064b932a30f | |||
| FDA-2020-V-1552-0007 | FDA | Laser Light Show FDA-2020-V-1552 | Variance Amendment Approval Letter from FDA CDRH to LaserAnimation Sollinger GmbH | Other | Approval for Variance (VRA) | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T22:36:57Z | 0 | 0 | 09000064b9327f85 | ||
| FDA-2025-P-7112-0003 | FDA | Requests that FDA determine whether Fluosol® (20% Intravascular Perfluorochemical Emulsion) approved under New Drug Application (NDA) 86-0909, held by Alpha Therapeutic Corporation, has been voluntarily withdrawn from sale for reasons of safety or effectiveness, pursuant to 21 CFR S 314.161 FDA-2025-P-7112 | Interim Response | Other | Letter(s) | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T22:17:54Z | 0 | 0 | 09000064b932a259 | ||
| FDA-2026-P-4021-0004 | FDA | Requests that the FDA determine whether the Reference Listed Drug (RLD) SPORANOX (ITRACONAZOLE) Oral Solution, 10mg/mL; under New Drug Application (NDA) N020657 held by JANSSEN PHARMACEUTICALS INC, was voluntarily withdrawn from commercial distribution, or withdrawn from sale for safety or efficacy reasons. FDA-2026-P-4021 | Relisting Notice Protamine Sulfate (Protamine Sulfate) IV Solution 50mg per mL | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T22:19:33Z | 0 | 0 | 09000064b9329751 | |||
| FDA-2026-H-6634-0001 | FDA | DAB Civil Money Penalty; Space Out Smoke Hickory LLC d/b/a Cosmic Smoke FDA-2026-H-6634 | Complaint | Other | Complaint | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T20:18:41Z | 0 | 0 | 09000064b932ecff | ||
| FDA-2026-P-6737-0010 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 8 - Repeated gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:50Z | 0 | 0 | 09000064b932a304 | |||
| FDA-2026-P-6737-0007 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 5 - Concentration-Dependent Bidirectional Modification of Evoked Synaptic Transmission by Gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:40Z | 0 | 0 | 09000064b932a301 | |||
| FDA-2026-P-6737-0006 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 4 - Gadolinium accelerates the migration of astrocyte via integrin signaling pathway | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:36Z | 0 | 0 | 09000064b932a300 | |||
| FDA-2026-P-6737-0023 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 21 - Influence blocking by Gadolinium in Calcium Diffusion | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:33Z | 0 | 0 | 09000064b932a313 | |||
| FDA-2026-P-6737-0041 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 39 - Delineating toxicity mechanisms associated with MRI contrast | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:37Z | 0 | 0 | 09000064b932a33b | |||
| FDA-2026-D-2698-0002 | FDA | Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability FDA-2026-D-2698 | Forms FDA 3542a and FDA 3542: Questions and Answers; Guidance for Industry | Other | Guidance | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-08-15T03:59:59Z | 2026-06-15T17:14:02Z | 1 | 0 | 09000064b932cc13 | |
| FDA-2025-P-7433-0005 | FDA | Requests that the FDA adopt, or incorporate into existing guidance, a risk-based regulatory framework specific to peptide therapeutics, with particular emphasis on delivery-route acceptability, dose sensitivity, and exposure variability. FDA-2025-P-7433 | Interim Response from FDA CDER to University of Illinois, College of Pharmacy | Other | Response(s) | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T23:48:58Z | 0 | 0 | 09000064b93318f1 | ||
| FDA-2024-V-1078-0005 | FDA | Laser Light Show FDA-2024-V-1078 | Variance Renewal Approval Letter from FDA CDRH to Dog From The Moon LLC | Other | Approval for Variance (VRA) | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T22:31:34Z | 0 | 0 | 09000064b9326ee6 | ||
| FDA-2026-P-4021-0003 | FDA | Requests that the FDA determine whether the Reference Listed Drug (RLD) SPORANOX (ITRACONAZOLE) Oral Solution, 10mg/mL; under New Drug Application (NDA) N020657 held by JANSSEN PHARMACEUTICALS INC, was voluntarily withdrawn from commercial distribution, or withdrawn from sale for safety or efficacy reasons. FDA-2026-P-4021 | Final Response | Other | Letter(s) | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T22:19:21Z | 0 | 0 | 09000064b9328a95 | ||
| FDA-2026-V-4560-0002 | FDA | Laser Light Show FDA-2026-V-4560 | Acknowledgment Letter from FDA DMB to DJZ Productions | Other | Acknowledgement Letter/Receipt | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T22:27:57Z | 0 | 0 | 09000064b92a571d | ||
| FDA-2026-P-6737-0044 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 42 - Altered Functional Mitochondrial Protein Levels in Plasma | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:47Z | 0 | 0 | 09000064b932a33e | |||
| FDA-2026-P-6737-0024 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 22 - Gadolinium deposition in bone tissues after contrast-enhanced | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:37Z | 0 | 0 | 09000064b932a314 | |||
| FDA-2026-P-6737-0021 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 19 - Gadolinium-based contrast agent toxicity | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:25Z | 0 | 0 | 09000064b932a311 | |||
| FDA-2026-N-6404-0001 | FDA | Amendment and Revocation of Organizational Information Regulations FDA-2026-N-6404 | Amendment and Revocation of Organizational Information Regulations | Rule | Final Rule | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T17:03:54Z | 2026-11998 | 0 | 0 | 09000064b932f2cf | ||
| FDA-2026-D-2698-0001 | FDA | Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability FDA-2026-D-2698 | Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T17:12:16Z | 2026-11966 | 0 | 0 | 09000064b932f27d | ||
| FDA-2026-P-6737-0005 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 3 - Gadolinium retention effect on macrophages | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:32Z | 0 | 0 | 09000064b932a275 | |||
| FDA-2026-P-6737-0037 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 35 - The Impact of Gadolinium on Quantitative Myelin Metrics | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:23Z | 0 | 0 | 09000064b932a337 | |||
| FDA-2026-P-6737-0018 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 16 - Immediate adverse reactions to gadolinium-based MR contrast | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:15Z | 0 | 0 | 09000064b932a30e | |||
| FDA-2026-P-6737-0015 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 13 - Prepubertal exposure to gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:05Z | 0 | 0 | 09000064b932a309 | |||
| FDA-2026-P-6789-0002 | FDA | Requests that the FDA review whether the two primary generic bicalutamide tablet suppliers can assure the safety, efficacy, and quality of bicalutamide tablets for the intended prostate cancer patient population. FDA-2026-P-6789 | Acknowledgement Letter from FDA DMB to Buchanan Ingersoll & Rooney PC | Other | Acknowledgement Letter/Receipt | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-16T00:58:01Z | 0 | 0 | 09000064b932ff3a | ||
| FDA-2004-V-0487-0012 | FDA | Laser Light Show FDA-2004-V-0487 | Variance Approval Letter from FDA CDRH to Clark Planetarium | Other | Approval for Variance (VRA) | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T21:56:44Z | 0 | 0 | 09000064b932a66a | ||
| FDA-2026-V-4031-0001 | FDA | Laser Light Show FDA-2026-V-4031 | Variance Application from David Wilson | Other | Application for Variance (VAR) | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T22:28:07Z | 0 | 0 | 09000064b927c69a | ||
| FDA-2018-N-3240-1005 | FDA | List of Bulk Drug Substances For Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Notice FDA-2018-N-3240 | Request for Extension from Collaborative for Evidence-Based Medicines | Other | Request for Extension | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-06-15T22:23:23Z | 0 | 0 | 09000064b9329d1b | ||
| FDA-2026-P-6737-0030 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 28 - Skin-Related Adverse Reactions in Gadolinium | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:28:56Z | 0 | 0 | 09000064b932a326 | |||
| FDA-2026-P-6737-0045 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 43 - An initial investigation of serum cytokine levels in patients with gadolinium retention | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:50Z | 0 | 0 | 09000064b932a33f | |||
| FDA-2026-P-6737-0040 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 38 - Ultrastructural Evidence of Dermal Gadolinium Deposits | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:34Z | 0 | 0 | 09000064b932a33a | |||
| FDA-2026-P-6737-0043 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 41 - Long-Term Treatment with Gadopentetic Acid or Gadodiamide | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:29:44Z | 0 | 0 | 09000064b932a33d | |||
| FDA-2026-P-6737-0008 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 6 - Literature case analysis of nephrogenic systemic fibrosis induced by gadolinium-based contrast agents | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:43Z | 0 | 0 | 09000064b932a302 | |||
| FDA-2026-P-6737-0003 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 1 - Gadolinium-Based Contrast Media Nephrotoxicity in Kidney Impairment | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:26Z | 0 | 0 | 09000064b932a273 | |||
| FDA-2026-P-6737-0012 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 10 - Gadolinium-Based Contrast Agent Accumulation and Toxicity | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:55Z | 0 | 0 | 09000064b932a306 | |||
| FDA-2026-P-6737-0009 | FDA | Requests that the FDA grant an emergency moratorium of gadolinium use for public health and safety and establishment of a national use registry. FDA-2026-P-6737 | Reference 7 - Incorporation of excess gadolinium into human bone from medical contrast agents | Supporting & Related Material | Background Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:27:46Z | 0 | 0 | 09000064b932a303 | |||
| EPA-HQ-OAR-2024-0419-0247 | EPA | Review of New Source Performance Standards for Stationary Combustion Turbines EPA-HQ-OAR-2024-0419 | PGen Petition for Reconsideration CT NSPS Final Rule | Supporting & Related Material | Petition | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T22:49:03Z | 0 | 0 | 09000064b92c40c3 | |||
| EPA-HQ-OPP-2024-0136-0011 | EPA | Notice of Receipt of New Active Ingredient, PDHP 68949 EPA-HQ-OPP-2024-0136 | Registration Decision for the New Active Ingredient PDHP 68949 | Supporting & Related Material | Decision | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T21:02:00Z | 0 | 0 | 09000064b931ecef | |||
| EPA-HQ-OPP-2024-0136-0010 | EPA | Notice of Receipt of New Active Ingredient, PDHP 68949 EPA-HQ-OPP-2024-0136 | Registration Notice and Stamped Labeling for PHC 68949 71771-16 | Supporting & Related Material | Permit, Registration | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T21:01:53Z | 0 | 0 | 09000064b931ecb4 | |||
| EPA-HQ-OPP-2025-0183-0009 | EPA | Pydiflumetofen: Pesticide Petition (PP# 4F9138) to Establish Inadvertent Tolerances for Pydiflumetofen In or On Sugarcane EPA-HQ-OPP-2025-0183 | Pydiflumetofen. Establishment of a Tolerance for Indirect or Inadvertent Residues in/on Sugarcane and Label Amendments to Reduce the Plant-Back Interval for Sugarcane and Add a Soil Use for Cottonseed subgroup 20C, Leafy greens subgroup 4-16A, and Vegetable, fruiting, group 8-10. Summary of Analytical Chemistry and Residue Data | Supporting & Related Material | Data | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T21:03:43Z | 0 | 0 | 09000064b930e2d0 | |||
| EPA-HQ-OPP-2025-3824-0004 | EPA | Tolerance petition - fenpropathrin and abamectin residues in or on all food/feed commodities EPA-HQ-OPP-2025-3824 | Valent BioSciences, LLC Notice of Filing Pesticide Petition by establishing a tolerance for residues of fenpropathrin in or on food and feed commodities at 0.9 parts per million (ppm) following widearea mosquito adulticide applications. | Supporting & Related Material | Petition | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:47:34Z | 0 | 0 | 09000064b913e70e | |||
| EPA-HQ-OPP-2023-0296-0003 | EPA | IN-11745: Sodium Nitrate (CAS Reg. No. 7631-99-4), Exemption from the Requirement of a Tolerance EPA-HQ-OPP-2023-0296 | Pesticide Tolerance; Exemptions, Petitions, Revocations, etc.: Sodium Nitrate in Pesticide Formulations | Rule | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-08-15T03:59:59Z | 2026-06-15T20:08:12Z | 2026-11941 | 1 | 0 | 09000064b932f1e7 | |
| EPA-HQ-OPP-2025-3824-0001 | EPA | Tolerance petition - fenpropathrin and abamectin residues in or on all food/feed commodities EPA-HQ-OPP-2025-3824 | Pesticide Tolerance; Exemptions, Petitions, Revocations, etc.: Residues of Pesticide Chemicals in or on Various Commodities—February 2026 | Proposed Rule | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-07-16T03:59:59Z | 2026-06-15T20:46:58Z | 2026-11942 | 1 | 0 | 09000064b932f4dd | |
| EPA-HQ-OPP-2026-0629-0002 | EPA | N-12631: 2-Propenoic acid, 2-methyl-, telomer with 1-dodecanethiol, and 2-methyloxirane polymer with oxirane monoether with 1,2-propanediol mono(2-methyl-2-propenoate) (CAS Reg No. 1186225-21-7), Exemption from the requirement of a tolerance EPA-HQ-OPP-2026-0629 | Pesticide Tolerance; Exemptions, Petitions, Revocations, etc.: Residues of Pesticide Chemicals in or on Various Commodities—February 2026 | Proposed Rule | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-07-16T03:59:59Z | 2026-06-15T21:06:29Z | 2026-11942 | 1 | 0 | 09000064b9327f86 | |
| EPA-HQ-OAR-2024-0419-0249 | EPA | Review of New Source Performance Standards for Stationary Combustion Turbines EPA-HQ-OAR-2024-0419 | Policy Integrity Comments on EDF Petition | Supporting & Related Material | Petition | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T22:49:03Z | 0 | 0 | 09000064b92c40c5 | |||
| EPA-HQ-OLEM-2020-0107-1564 | EPA | Hazardous and Solid Waste Management System: Disposal of Coal Combustion Residuals from Electric Utilities; Legacy Surface Impoundments EPA-HQ-OLEM-2020-0107 | OLEM April 30, 2026, Response to April 17 Request for Extended Comment Period and In-Person Hearing from Sierra Club et al. | Supporting & Related Material | Letter | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T21:36:59Z | 0 | 0 | 09000064b9329b68 | |||
| EPA-HQ-OPP-2025-0183-0011 | EPA | Pydiflumetofen: Pesticide Petition (PP# 4F9138) to Establish Inadvertent Tolerances for Pydiflumetofen In or On Sugarcane EPA-HQ-OPP-2025-0183 | Pydiflumetofen. Human Health Risk Assessment to Support a Tolerance for Indirect or Inadvertent Residues in/on Sugarcane and Label Amendments to Reduce the Plant-Back Interval for Sugarcane and Add a Soil Use for Cottonseed subgroup 20C, Leafy greens subgroup 4-16A, and Vegetable, fruiting, group 8-10 | Supporting & Related Material | Risk Assessment | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T21:03:50Z | 0 | 0 | 09000064b930e9ee | |||
| EPA-HQ-OPP-2025-2565-0004 | EPA | Afidopyropen; tolerances for residues. EPA-HQ-OPP-2025-2565 | Pesticide Product Registration: Applications for New Uses (February 2026) | Notice | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T04:00:00Z | 2026-07-16T03:59:59Z | 2026-06-15T20:52:06Z | 2026-11944 | 1 | 0 | 09000064b9330660 | |
| EPA-HQ-OPP-2026-0334-0001 | EPA | Pesticide Product Registration; Receipt of Applications for New Uses EPA-HQ-OPP-2026-0334 | Pesticide Product Registration: Applications for New Uses (February 2026) | Notice | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T20:59:05Z | 2026-11944 | 0 | 0 | 09000064b932f23a | |||
| EPA-HQ-OPPT-2026-1189-0128 | EPA | SACC peer review of the draft risk evaluations for 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethylcyclopenta [g]-2-benzopyran (HHCB) and phthalic anhydride and the draft hazard assessments for o-dichlorobenzene (o-DCB) and p-dichlorobenzene (p-DCB) EPA-HQ-OPPT-2026-1189 | Bioaccumulation and bioconcentration factors figure presented by Committee member Daniel Schlenk | Supporting & Related Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T21:38:16Z | 0 | 0 | 09000064b9325015 | ||||
| EPA-HQ-OPP-2026-0332-0002 | EPA | Notice of filing of petitions and request for comment EPA-HQ-OPP-2026-0332 | Pesticide Tolerance; Exemptions, Petitions, Revocations, etc.: Residues of Pesticide Chemicals in or on Various Commodities—February 2026 | Proposed Rule | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T19:48:53Z | 2026-11942 | 0 | 0 | 09000064b932e8f9 | |||
| EPA-HQ-OPPT-2026-1189-0131 | EPA | SACC peer review of the draft risk evaluations for 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethylcyclopenta [g]-2-benzopyran (HHCB) and phthalic anhydride and the draft hazard assessments for o-dichlorobenzene (o-DCB) and p-dichlorobenzene (p-DCB) EPA-HQ-OPPT-2026-1189 | Additional references from the SACC | Supporting & Related Material | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T21:38:32Z | 0 | 0 | 09000064b932a662 | ||||
| EPA-HQ-OPP-2023-0296-0004 | EPA | IN-11745: Sodium Nitrate (CAS Reg. No. 7631-99-4), Exemption from the Requirement of a Tolerance EPA-HQ-OPP-2023-0296 | IN-11745; Sodium Nitrate. Human Health Risk Assessment and Ecological Effects Assessment to Support Inert Ingredient Approval for use in Pesticide Formulations | Supporting & Related Material | Risk Assessment | 2026-06-15T04:00:00Z | 2026 | 6 | 2026-06-15T22:14:08Z | 0 | 0 | 09000064b920a4ba |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;